Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MCL1 as putative target in pancreatoblastoma.
Reissig TM, Uhrig S, Jost PJ, Luchini C, Vicentini C, Liffers ST, Allgäuer M, Adsay V, Scarpa A, Lawlor RT, Fröhling S, Stenzinger A, Klöppel G, Schildhaus HU, Siveke JT. Reissig TM, et al. Among authors: frohling s. Virchows Arch. 2022 Aug;481(2):265-272. doi: 10.1007/s00428-022-03349-w. Epub 2022 Jun 7. Virchows Arch. 2022. PMID: 35668118 Free PMC article.
Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.
Budczies J, Bockmayr M, Denkert C, Klauschen F, Gröschel S, Darb-Esfahani S, Pfarr N, Leichsenring J, Onozato ML, Lennerz JK, Dietel M, Fröhling S, Schirmacher P, Iafrate AJ, Weichert W, Stenzinger A. Budczies J, et al. Among authors: frohling s. Genes Chromosomes Cancer. 2016 Aug;55(8):626-39. doi: 10.1002/gcc.22365. Epub 2016 May 30. Genes Chromosomes Cancer. 2016. PMID: 27106868
Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma.
Dieter SM, Heining C, Agaimy A, Huebschmann D, Bonekamp D, Hutter B, Ehrenberg KR, Fröhlich M, Schlesner M, Scholl C, Schlemmer HP, Wolf S, Mavratzas A, Jung CS, Gröschel S, von Kalle C, Eils R, Brors B, Penzel R, Kriegsmann M, Reuss DE, Schirmacher P, Stenzinger A, Federspil PA, Weichert W, Glimm H, Fröhling S. Dieter SM, et al. Among authors: frohling s. Ann Oncol. 2017 Jan 1;28(1):142-148. doi: 10.1093/annonc/mdw446. Ann Oncol. 2017. PMID: 27687311 Free article.
Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification.
Gröschel S, Bommer M, Hutter B, Budczies J, Bonekamp D, Heining C, Horak P, Fröhlich M, Uhrig S, Hübschmann D, Geörg C, Richter D, Pfarr N, Pfütze K, Wolf S, Schirmacher P, Jäger D, von Kalle C, Brors B, Glimm H, Weichert W, Stenzinger A, Fröhling S. Gröschel S, et al. Among authors: frohling s. Cold Spring Harb Mol Case Stud. 2016 Nov;2(6):a001180. doi: 10.1101/mcs.a001180. Cold Spring Harb Mol Case Stud. 2016. PMID: 27900363 Free PMC article.
PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma.
Budczies J, Mechtersheimer G, Denkert C, Klauschen F, Mughal SS, Chudasama P, Bockmayr M, Jöhrens K, Endris V, Lier A, Lasitschka F, Penzel R, Dietel M, Brors B, Gröschel S, Glimm H, Schirmacher P, Renner M, Fröhling S, Stenzinger A. Budczies J, et al. Among authors: frohling s. Oncoimmunology. 2017 Jan 27;6(3):e1279777. doi: 10.1080/2162402X.2017.1279777. eCollection 2017. Oncoimmunology. 2017. PMID: 28405504 Free PMC article.
Precision oncology based on omics data: The NCT Heidelberg experience.
Horak P, Klink B, Heining C, Gröschel S, Hutter B, Fröhlich M, Uhrig S, Hübschmann D, Schlesner M, Eils R, Richter D, Pfütze K, Geörg C, Meißburger B, Wolf S, Schulz A, Penzel R, Herpel E, Kirchner M, Lier A, Endris V, Singer S, Schirmacher P, Weichert W, Stenzinger A, Schlenk RF, Schröck E, Brors B, von Kalle C, Glimm H, Fröhling S. Horak P, et al. Among authors: frohling s. Int J Cancer. 2017 Sep 1;141(5):877-886. doi: 10.1002/ijc.30828. Epub 2017 Jun 21. Int J Cancer. 2017. PMID: 28597939 Free article.
Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
Czink E, Kloor M, Goeppert B, Fröhling S, Uhrig S, Weber TF, Meinel J, Sutter C, Weiss KH, Schirmacher P, Doeberitz MVK, Jäger D, Springfeld C. Czink E, et al. Among authors: frohling s. Cold Spring Harb Mol Case Stud. 2017 Sep 1;3(5):a001974. doi: 10.1101/mcs.a001974. Print 2017 Sep. Cold Spring Harb Mol Case Stud. 2017. PMID: 28619747 Free PMC article.
Genomics of Immunotherapy-Associated Hyperprogressors-Letter.
Forschner A, Niessner H, Möller Y, Horak P, Fröhlich M, Warsow G, Stenzinger A, Fröhling S, Glimm H, Klumpp B, Garbe C, Sinnberg T. Forschner A, et al. Among authors: frohling s. Clin Cancer Res. 2017 Oct 15;23(20):6374-6375. doi: 10.1158/1078-0432.CCR-17-1480. Clin Cancer Res. 2017. PMID: 29030332 No abstract available.
Integrative genomic and transcriptomic analysis of leiomyosarcoma.
Chudasama P, Mughal SS, Sanders MA, Hübschmann D, Chung I, Deeg KI, Wong SH, Rabe S, Hlevnjak M, Zapatka M, Ernst A, Kleinheinz K, Schlesner M, Sieverling L, Klink B, Schröck E, Hoogenboezem RM, Kasper B, Heilig CE, Egerer G, Wolf S, von Kalle C, Eils R, Stenzinger A, Weichert W, Glimm H, Gröschel S, Kopp HG, Omlor G, Lehner B, Bauer S, Schimmack S, Ulrich A, Mechtersheimer G, Rippe K, Brors B, Hutter B, Renner M, Hohenberger P, Scholl C, Fröhling S. Chudasama P, et al. Among authors: frohling s. Nat Commun. 2018 Jan 10;9(1):144. doi: 10.1038/s41467-017-02602-0. Nat Commun. 2018. PMID: 29321523 Free PMC article.
300 results